Affibody starts breast cancer tracer trial
This article was originally published in Clinica
Executive Summary
Swedish firm Affibody has been given the go-ahead to start an exploratory clinical trial for a new molecular imaging agent for breast cancer. The tracer could reduce the need for painful biopsies in women, claimed the Stockholm company.